CNS Biomarker Detection

The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, will transform the way brain injuries and diseases are diagnosed.

Simoa assays can detect neurological biomarkers associated with brain injury and disease at much earlier stages to understand the long-term effects and disease pathology. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS)  and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.

Latest News

Alzheimer’s disease is a dangerous and ultimately fatal form of dementia, and according to recent data from the Centers for Disease Control (CDC), Alzheimer’s is the sixth leading cause of death in the United States, accountin
Quanterix Corp, Lexington, Mass, has launched the Simoa Neurology 4-Plex A assay (N4PA).